silodosin / Generic mfg. - LARVOL DELTA

INTRAVASCULAR LARGE B-CELL LYMPHOMA DIAGNOSED BY RENAL BIOPSY PRESENTING WITH NEPHROTIC SYNDROME (ISN-WCN 2026) - "His past history included hypertension, dyslipidemia, and chronic obstructive pulmonary disease, treated with amlodipine, atorvastatin, indacaterol, and silodosin...R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) was initiated, followed by high-dose methotrexate for CNS prophylaxis...This case emphasizes the importance of considering hematologic malignancy in the differential diagnosis of nephrotic syndrome with unexplained fever, even in the absence of hematologic abnormalities. Early renal biopsy allowed timely R-CHOP chemotherapy and resulted in favorable clinical and renal outcomes."

Biopsy • B Cell Lymphoma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diffuse Large B Cell Lymphoma • Dyslipidemia • Glomerulonephritis • Hematological Malignancies • Hypertension • Immunology • Large B Cell Lymphoma • Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Renal Cell Carcinoma • Renal Disease • Respiratory Diseases • BCL6 • CD20 • IL2 • IRF4 • PTPRC

Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS). (PubMed, Aging Male) - "Reports of adverse events (AEs) in male BPH patients receiving AUA guideline-recommended drugs including α-1 blockers (tamsulosin, silodosin, doxazosin, and alfuzosin), 5ARIs (finasteride and dutasteride), and tadalafil were extracted. Sixteen significant AEs were detected, including pollakiuria, gynecomastia, breast pain and so on, with distinct reporting patterns across drug classes. This large-scale pharmacovigilance analysis identified distinct post-marketing safety signals among guideline-recommended pharmacotherapies for BPH, confirming known risks and suggesting potential novel adverse-event signals warranting further investigation."

Adverse events • Journal • Real-world evidence • Retrospective data • Benign Prostatic Hyperplasia • Pain

Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial (clinicaltrials.gov) - P4 | N=140 | Not yet recruiting | Sponsor: Ain Shams University

New P4 trial • Benign Prostatic Hyperplasia

Effect of Preoperative Silodosin on Outcomes of Ureteroscopy for Ureterolithiasis: A Systematic Review and Meta-Analysis (AUA 2026) - No abstract available

Retrospective data • Review

Efficacy and safety of α1-adrenergic blockers after extracorporeal shock wave lithotripsy in pediatric kidney stones. (PubMed, Pediatr Surg Int) - "Adjunctive therapy with α1-blockers after ESWL in children with urolithiasis improves treatment efficacy, shortens stone expulsion time, reduces pain, and demonstrates a favorable safety profile. An optimal timeframe for efficacy assessment is 6 days post-ESWL."

Journal • Nephrology • Pain • Pediatrics • Renal Calculi • Urolithiasis

Molecular insights into Silodosin's anti-cancer effects: a promising repurposing strategy for breast cancer. (PubMed, Cell Death Discov) - "While its known α1A-AR antagonism may contribute to its effects, silodosin could also act as an ER ligand, modulating estrogen-driven pathways essential in breast cancer development. This study provides the first experimental and computational evidence supporting the repurposing of silodosin as a potential multi-targeted therapeutic agent for breast cancer, opening promising new opportunities for patients with limited treatment options and encouraging further preclinical and clinical studies."

Journal • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER

Preparation of Two Process-Related Impurities of a Key Intermediate of Silodosin Under Baeyer-Villiger and Fenton Conditions. (PubMed, Molecules) - "Furthermore, by adding 20 mM FeCl3 into the above 10% hydrogen peroxide solution, IDI became the major product in a yield of ~43% under this Fenton reaction-like condition. The probable formation mechanism of IDI was discussed and validated in the context of certain structurally similar substrates."

Journal

Use of Alpha-Blockers Before RIRS: Assessment of Factors for Successful Ureteral Access Sheath Insertion. A Randomized Clinical Study (ChiCTR) - P=N/A | N=140 | Completed | Sponsor: St. Luke’s Clinical Hospital Russian Federation; St. Luke’s Clinical Hospital Russian Federation

New trial • Renal Calculi • Urolithiasis

Robot-assisted Reduction Pyeloplasty with 3D Image Navigation for Adult Giant Hydro-nephrosis: Technique and Clinical Outcomes. (PubMed, Int Braz J Urol) - "In studies with ≥10 days of preoperative use, silodosin significantly improved SFR (RR 1.17; 95% CI: 1.10-1.26; p < 0.00001). Preoperative silodosin reduces ureteral injuries, operative time, and complications, supporting its use to improve safety and efficiency of URS for ureterolithiasis."

Clinical • Clinical data • Journal • Review • Nephrology • Renal Calculi

Impact of Preoperative Silodosin on Ureteroscopy Outcomes for Ureterolithiasis: A Systematic Review and Meta-Analysis. (PubMed, Int Braz J Urol) - "In studies with ≥10 days of preoperative use, silodosin significantly improved SFR (RR 1.17; 95% CI: 1.10-1.26; p < 0.00001). Preoperative silodosin reduces ureteral injuries, operative time, and complications, supporting its use to improve safety and efficiency of URS for ureterolithiasis."

Clinical • Journal • Retrospective data • Review • Renal Calculi

The use of Silodosin in Ureterolithiasis is the Hot Topic in this Number of International Brazilian Journal of Urology. (PubMed, Int Braz J Urol) - No abstract available

Journal • Urology

A Novel 1,3-Sigmatropic Rearrangement in an Iminium Ion Generated in Collision-Induced Decomposition During Electrospray Ionization High Resolution Multistage Mass Spectrometry. (PubMed, Rapid Commun Mass Spectrom) - "Elucidation of such an intra-molecular rearrangement mechanism not only enriches our understanding of the gas phase dissociation chemistry, but also should facilitate future rapid structural characterization of unknown pharmaceutical impurities and metabolites using multistage mass spectrometric analysis."

Journal

Efficacy of alpha-blockers in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials between 2010 and 2025. (PubMed, Arab J Urol) - "Network meta-analysis revealed efficacy ranking favoring at first terazosin, followed by doxazosin then, silodosin then, tamsulosin then, alfuzosin and last the least effective was naftopidil. While tamsulosin remains the most studied agent, our network meta-analysis suggests terazosin and doxazosin may offer superior efficacy. The favorable risk-benefit profile supports routine use of alpha-blockers for appropriately selected patients with ureteral stones."

Journal • Retrospective data • Review • Pain • Renal Calculi • Urolithiasis

Understanding the Impact of Sustainable Pharmaceutical Packaging on the Chemical Stability of Silodosin. (PubMed, Pharmaceutics) - "These findings highlight the critical role of packaging in pharmaceutical stability. While AquaBa® emerges as the preferred option for SLD soft capsules, formulation optimization remains necessary to limit impurity formation, extend shelf life, and ensure regulatory compliance."

Journal • Benign Prostatic Hyperplasia

3D printed sex-specific medicines: Excipient-mediated modulation boosts systemic drug exposure by more than three-fold in male rats. (PubMed, J Control Release) - "This study examined how 3D printed formulations containing PEG 2000 influence the pharmacokinetics of silodosin, a P-gp substrate drug used for the treatment of benign prostatic hyperplasia (BPH) in ageing men, using male and female Wistar rats...By integrating biological variables such as sex into formulation design and leveraging the promising potential of 3D printing, this study demonstrates for the first time how excipient functionality can be harnessed to develop sex-specific oral therapies and advance personalised oral drug delivery. These findings pave the way for the future clinical translation of sex- and excipient-driven therapeutic approaches."

Journal • Preclinical • Benign Prostatic Hyperplasia

Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanisms. (PubMed, F1000Res) - "In the xenograft study, tumor size, body weight, and organ weight were significantly attenuated by the test drugs compared with the standard cisplatin. KRAS and ERK2 are components of EGFR-associated signaling pathways. Hence, acenocoumarol and silodosin can be further explored as repurposed candidates in future preclinical and clinical studies."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CASP3 • KRAS

The Comparative Effectiveness of PDE5 Inhibitors and β3 Agonists Versus α-Blockers in Medical Expulsive Therapy for Distal Ureteric Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Cureus) - "The objective of this systematic review and meta-analysis was to compare the efficacy and safety of emerging pharmacologic therapies, namely tadalafil and mirabegron, with traditional alpha-blockers, such as tamsulosin and silodosin, as medical expulsive therapies (METs) for distal ureteric stones measuring ≤10 or <5 mm. However, given that pooled results are not statistically significant, the following require further evaluation. On the contrary, alpha-blockers are still better than mirabegron, but again, this is not statistically significant enough to prove their supremacy."

HEOR • Journal • Retrospective data • Review • Cardiovascular • Hypertension • Pain • Renal Calculi • Urolithiasis

Differential Risks of Dementia, Depression, and Injury Among Common α-Blockers, with Tamsulosin as the Reference Drug: A Real-World Cohort Study in Men with Lower Urinary Tract Symptoms. (PubMed, J Clin Med) - "Patients were grouped by α-blocker type-tamsulosin, doxazosin, terazosin, alfuzosin, silodosin, or prazosin-and matched 1:1 using propensity scores to adjust for demographic, clinical, and psychosocial variables. Given its favorable profile, alfuzosin may be the preferred agent in patients at elevated risk of cognitive or psychiatric disorders. These findings highlight the need for individualized α-blocker selection and long-term pharmacovigilance in BPH management."

Journal • Real-world evidence • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Dementia • Depression • Mental Retardation • Oncology • Psychiatry

Silodosin in treating men With BPH-associated lower urinary tract Symptoms: A systematic review and network meta-analysis. (PubMed, Int J Surg) - "Silodosin is highly effective for BPH-LUTS, particularly for voiding symptoms, but carries a elevated risk of ejaculatory dysfunction. Combination with tadalafil may enhance urinary flow. Clinicians should weigh efficacy against adverse events; further trials are needed to confirm long-term benefits."

Journal • Retrospective data • Benign Prostatic Hyperplasia

Comparative evaluation of safety and efficacy of dapoxetine, silodosin, and citalopram in the management of premature ejaculation: a randomized clinical trial. (PubMed, BMC Urol) - P4 | "In this direct head-to-head comparison of active treatments for lifelong PE, daily citalopram (20 mg) demonstrated superior efficacy in prolonging IELT and improving psychosocial outcomes compared to daily or on-demand dapoxetine and silodosin. The findings suggest that citalopram is a highly effective first-line option, while the dose-dependent efficacy of dapoxetine and the distinct side-effect profile of silodosin provide alternative considerations for personalized treatment strategies."

Clinical • Journal • Sexual Disorders

Comparison of Preoperative Alpha-Blocker Therapy Versus Placebo Before Ureterorenoscopy and Lithotripsy for Distal Ureteral Stones. (PubMed, Cureus) - "In Group A, URS and lithotripsy were performed after two weeks of alpha-blocker therapy (silodosin 8 mg once daily), while in Group B, URS and lithotripsy were performed after two weeks without alpha-blocker therapy (placebo group)...The use of alpha-blockers is recommended to enhance procedural outcomes and minimize the risk of complications during URS and lithotripsy. Further studies with larger sample sizes and longer follow-up periods are warranted to confirm these findings."

Journal • Benign Prostatic Hyperplasia • Nephrology • Renal Calculi • Transplantation • Urology

Management of acute urinary retention in men with benign prostatic hyperplasia: Literature review and guidelines from the French Urological Association Male LUTS Panel (CTMH). (PubMed, Fr J Urol) - "These CTMH guidelines provide evidence-based recommendations for AUR management, emphasizing alpha-blocker therapy before trial without catheter and considering patient-specific factors when selecting drainage methods. Further research is needed to optimize surgical timing and technique selection."

Clinical guideline • Journal • Review • Anesthesia • Benign Prostatic Hyperplasia

Efficacy of daily silodosin 8 mg as a potential reversible male contraceptive: A prospective placebo controlled study. (PubMed, Int Urol Nephrol) - "Silodosin 8 mg yields a better sperm suppression results as on-demand male contraception after 3 months of continuous daily oral intake when compared to placebo, associated with pregnancy rate of 4% and higher but tolerable side effects."

Journal

E3 ligase CHIP restoration facilitates the effect of α1-adrenoceptor blockage on alleviating lipopolysaccharide-caused cardiac fibrosis via downregulating TGF-BR1 expression and Smad2/3 activation. (PubMed, Mol Biomed) - "Furthermore, we innovatively revealed that α1A-AR is the dominant α1-AR subtype in CFs, and its specific antagonist, silodosin, eliminated NE-mediated CFs differentiation and LPS-induced myocardial fibrosis, which was consistent with the action of prazosin. These findings demonstrate the protective effect of α1-AR blockage against LPS-mediated myocardial fibrosis, which is achieved by directly inhibiting the PKC-p38-Smad2/3 signaling pathway and promoting TGF-BR1 downregulation through restoring CHIP expression."

Journal • Fibrosis • Immunology • Infectious Disease • Septic Shock • Targeted Protein Degradation • JUN • SMAD2 • ST13 • TGFB1

Comparing Tamsulosin vs. Silodosin prior to Ureteroscopy: A Network Meta-Analysis of Randomized Controlled Trials. (PubMed, World J Urol) - "Silodosin and Tamsulosin are both viable options pre-URS, with Silodosin potentially yielding shorter operative time, less ureteral dilatation required and higher SAR. However, these differences are non-significant and stem from indirect estimates. Therefore, randomized head-to-head comparison trials are warranted."

Clinical • Journal • Retrospective data • Review • Renal Calculi • Urolithiasis